We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Joyce
Daniels
j.daniels@imperial.ac.uk
Laura
McLeavy
laura.mcleavy13@imperial.ac.uk
Dr
Laura
Kenny
l.kenny@imperial.ac.uk
Malignant neoplasm of breast
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
HER2 is a protein expressed on 20% of breast cancers. This study will investigate a new type of scan to see if HER2 can be detected using imaging, the results will be compared to conventional biopsies. 16 patients with metastatic breast cancer (8 with HER2 positive and 8 with HER2 negative breast cancer, determined using the most recent biopsy) will be recruited. Dynamic PET imaging over 90 minutes using [18F]GE-226, which is a radiolabelled Affibody tracer which binds to the HER2 receptor, and radial artery sampling will be performed to establish the pharmacokinetic profile of the investigational tracer, [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Safety data will be collected and reviewed for 24 hours post [18F]GE-226 administration.Tumour uptake in individual metastases > cm (as well as the target lesion > = 2cm will be reported. Uptake will be compared between HER2 positive and HER2 negative tumours between patients, and between tumour and non-tumour tissue.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Imaging;
You can take part if:
You may not be able to take part if:
1. Pregnant or lactating women. 2. History of cardiac disease (myocardial infarction, arrhythmias requiring therapy, symptomatic valvular disease, cardiomyopathy, or pericarditis). 3. Evidence of significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial. 4. Participants with severe claustrophobia or who are unable to lie flat or fit into the scanner (> = 350 lbs (160 Kg)). 5. Prior use within 14 days of enrolment or concurrent therapy with any other investigational agent. 6. Patients classified as radiation workers 7. Patients on therapeutic doses of anticoagulants, or with a raised prothrombin time
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Laura
McLeavy
laura.mcleavy13@imperial.ac.uk
Joyce
Daniels
j.daniels@imperial.ac.uk
Dr
Laura
Kenny
l.kenny@imperial.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 34394
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
